Recent patent disclosures illustrate how modern medicinal chemistry advances by aligning biological insight with chemical modality, formulation rigor, and molecular measurement. Targeted protein degradation to overcome resistance, solid-state engineering to ensure sustained pathway suppression, and single-cell genomic profiling to resolve metastatic biology together demonstrate how therapeutic impact emerges when perturbation, delivery, and biological observability are coherently integrated.
Renner et al. (2026) studied this question.